## Bristol Financials |

BMY -- USA Stock | ## Report: |

Understanding current and past Bristol Myers Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. Bristol Myers Total Assets Per Share are fairly stable at the moment as compared to the past year. Bristol Myers reported Total Assets Per Share of 57.73 in 2019. Net Current Assets as percentage of Total Assets is likely to grow to 13.00 in 2020, whereas Net Income Per Employee is likely to drop slightly above 106.8

With this module, you can analyze Bristol financials for your investing period. You should be able to track the changes in Bristol Myers individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

**K**in 2020. Use fundamental data analysis to double-check all available reported financial drivers of Bristol Myers Squibb to find out if markets are presently mispricing the company. We were able to interpolate and analyze data for thirty-eight available fundamental indicators for Bristol Myers Squibb, which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Bristol Myers Squibb financials, including its price to earning, book value per share, current liabilities, as well as the relationship between the net income and beta . Given that Bristol Myers Squibb has a price to earning of 113.27 X, we suggest you to validate Bristol Myers Squibb prevailing market performance to make sure the company can sustain itself down the road. Use Bristol Myers to protect your portfolios against small markets fluctuations. The stock experiences a somewhat bearish sentiment, but market may correct it shortly. Check odds of Bristol Myers to be traded at $55.71 in 30 days.#### Search Fundamentals

Bristol Select Account or Indicator |

## Chance of Financial Distress

Bristol Myers Squibb has

**less than 34 (%) percent**chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Bristol Myers stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info## Bristol Myers Company Summary

Bristol Myers competes with Gilead Sciences, Merck, Grifols S, Johnson Johnson, and GlaxoSmithKline PLC. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 30000 people.Foreign Associate | Mexico |

Specialization | Healthcare, Drug Manufacturers - General |

Instrument | USA Stock View All |

Exchange | BATS Exchange |

CIK Number | 0000014272 |

ISIN | US1101221083 |

CUSIP | 110122108 |

Region | North America |

Location | New York; U.S.A |

Business Address | 430 E 29th |

Sector | Healthcare |

Industry | Drug Manufacturers?General |

Benchmark | DOW |

Website | www.bms.com |

Phone | 212 546 4020 |

Related Entity | BMY |

Currency | USD - US Dollar |

## Bristol Myers Key Financial Ratios

Return On Asset | 5.82 % | ||

Profit Margin | 3.08 % | ||

Operating Margin | 37.35 % |

## Bristol Myers Key Balance Sheet Accounts

2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 (projected) | ||

Inventories | 1.56 B | 1.22 B | 1.24 B | 1.17 B | 1.2 B | 4.29 B | 4.63 B | |

Receivables | 2.32 B | 3.16 B | 4.01 B | 5.09 B | 5.35 B | 7.68 B | 8.29 B | |

Accounts Payable | 2.49 B | 1.56 B | 1.66 B | 2.25 B | 1.89 B | 2.44 B | 2.56 B | |

Total Assets | 33.75 B | 31.75 B | 33.71 B | 33.55 B | 34.99 B | 129.94 B | 140.2 B | |

Current Assets | 14.61 B | 10.41 B | 13.7 B | 14.85 B | 17.72 B | 29.35 B | 24.48 B | |

Assets Non Current | 19.14 B | 21.33 B | 20 B | 18.7 B | 17.27 B | 100.59 B | 108.53 B | |

Cash and Equivalents | 5.57 B | 2.38 B | 4.24 B | 5.42 B | 6.91 B | 12.35 B | 13.32 B | |

Total Debt | 7.83 B | 6.69 B | 6.71 B | 7.96 B | 7.35 B | 46.73 B | 50.42 B | |

Debt Current | 590 M | 139 M | 992 M | 987 M | 1.7 B | 3.35 B | 3.61 B | |

Debt Non Current | 7.24 B | 6.55 B | 5.72 B | 6.97 B | 5.65 B | 43.39 B | 46.81 B | |

Deferred Revenue | 1.52 B | 1.94 B | 1.59 B | 1.31 B | 537 M | 483.3 M | 496.02 M | |

Shareholders Equity | 14.85 B | 14.27 B | 16.18 B | 11.74 B | 14.03 B | 51.6 B | 55.67 B | |

Inventory | 1.56 B | 1.22 B | 1.24 B | 1.17 B | 1.2 B | 4.29 B | 4.63 B | |

Investments | 6.27 B | 6.54 B | 4.83 B | 3.87 B | 3.62 B | 3.81 B | 3.97 B | |

Investments Current | 1.86 B | 1.89 B | 2.11 B | 1.39 B | 1.85 B | 3.05 B | 2.67 B | |

Total Liabilities | 18.77 B | 17.32 B | 17.36 B | 21.7 B | 20.86 B | 78.25 B | 84.42 B | |

Current Liabilities | 8.46 B | 8.02 B | 8.84 B | 9.56 B | 10.65 B | 18.3 B | 15.18 B | |

Tax Assets | 2.56 B | 2.84 B | 3 B | 1.61 B | 815 M | 510 M | 523.42 M | |

Tax Liabilities | 822 M | 1.31 B | 1.12 B | 3.78 B | 19 M | 6.45 B | 6.96 B |

## Bristol Myers Key Income Statement Accounts

2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 (projected) | ||

Direct Expenses | 3.93 B | 3.91 B | 4.95 B | 6.07 B | 6.55 B | 8.08 B | 6.51 B | |

Consolidated Income | 2.03 B | 1.63 B | 4.51 B | 975 M | 4.95 B | 3.46 B | 3.52 B | |

Cost of Revenue | 3.93 B | 3.91 B | 4.97 B | 6.01 B | 6.47 B | 8.08 B | 7.34 B | |

Gross Profit | 11.95 B | 12.65 B | 14.46 B | 14.76 B | 16.09 B | 18.07 B | 17.73 B | |

Net Income | 2 B | 1.56 B | 4.46 B | 1.01 B | 4.92 B | 3.44 B | 3.32 B | |

Operating Expenses | 9.57 B | 10.57 B | 8.54 B | 9.63 B | 10.13 B | 13.09 B | 12.5 B | |

Operating Income | 2.38 B | 2.08 B | 5.92 B | 5.13 B | 5.97 B | 4.97 B | 4.52 B | |

Revenues | 15.88 B | 16.56 B | 19.43 B | 20.78 B | 22.56 B | 26.14 B | 25.07 B | |

Income Tax Expense | 352 M | 446 M | 1.41 B | 4.16 B | 1.02 B | 1.51 B | 1.51 B |

## Bristol Myers Key Cash Accounts

2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 (projected) | ||

Capital Expenditure | (526 M) | (820 M) | (1.22 B) | (1.05 B) | (951 M) | (836 M) | (902 M) | |

Depreciation Amortization and Accretion | 467 M | 376 M | 382 M | 789 M | 637 M | 1.75 B | 1.88 B | |

Net Cash Flow or Change in Cash and Cash Equivalents | 1.99 B | (3.19 B) | 1.85 B | 1.18 B | 1.49 B | 5.91 B | 6.38 B | |

Net Cash Flow Business Acquisitions and Disposals | 3.37 B | (403 M) | 975 M | 10 M | 3 M | (8.78 B) | (9.01 B) | |

Issuance Purchase of Equity Shares | 131 M | 288 M | (231 M) | (2.47 B) | (320 M) | (7.3 B) | (7.49 B) | |

Issuance Repayment of Debt Securities | (432 M) | (1.14 B) | 110 M | 991 M | (548 M) | 17.65 B | 19.05 B | |

Payment of Dividends and Other Cash Distributions | (2.4 B) | (2.48 B) | (2.55 B) | (2.58 B) | (2.61 B) | (2.68 B) | (2.89 B) | |

Net Cash Flow from Financing | (2.44 B) | (3.62 B) | (2.65 B) | (4.08 B) | (3.54 B) | 7.62 B | 8.22 B | |

Net Cash Flow from Investing | 1.22 B | (1.57 B) | 1.48 B | (66 M) | (874 M) | (9.77 B) | (10.03 B) | |

Net Cash Flow Investment Acquisitions and Disposals | (1.62 B) | (349 M) | 1.72 B | 979 M | 74 M | (152 M) | (164 M) | |

Net Cash Flow from Operations | 3.15 B | 2.1 B | 3.06 B | 5.28 B | 5.94 B | 8.07 B | 6.96 B | |

Effect of Exchange Rate Changes on Cash | 58 M | (95 M) | (33 M) | 52 M | (41 M) | (9 M) | (9.24 M) | |

Share Based Compensation | 213 M | 235 M | 205 M | 199 M | 221 M | 441 M | 358.21 M |

## Bristol Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myers's current stock value. Our valuation model uses many indicators to compare Bristol Myers value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol Myers competition to find correlations between indicators driving Bristol Myers's intrinsic value. More Info. Bristol Myers Squibb is rated

**fourth**in retained earnings category among related companies. It is rated**below average**in net income category among related companies making up about 0.03 of Net Income per Retained Earnings. The ratio of Retained Earnings to Net Income for Bristol Myers Squibb is roughly 38.80 . Bristol Myers Net Income is fairly stable at the moment as compared to the past year. Bristol Myers reported Net Income of 3.44 Billion in 2019## Bristol Myers Squibb Systematic Risk

The output start index for this execution was nine with a total number of output elements of fifty-two. The Beta measures systematic risk based on how returns on Bristol Myers Squibb correlated with the market. If Beta is less than 0 Bristol Myers generally moves in the opposite direction as compared to the market. If Bristol Myers Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bristol Myers Squibb is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bristol Myers is generally in the same direction as the market. If Beta > 1 Bristol Myers moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

## About Bristol Myers Financials

What exactly are Bristol Myers Financials? Typically, a company's financial statements are the reports that show the financial position of the company. There are three primary documents that fall into the category of financial statements. These documents include Bristol Myers income statement, its balance sheet, and the statement of cash flows. Potential Bristol Myers investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Bristol Myers investors may use each financial statement separately, they are all related. The changes in Bristol Myers's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol Myers's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

2017 | 2018 | 2019 | 2020 (projected) | |

Receivables | 5.09 B | 5.35 B | 7.68 B | 8.29 B |

Inventories | 1.17 B | 1.2 B | 4.29 B | 4.63 B |

## Bristol Myers Thematic Clasifications

Bristol Myers Squibb is part of several thematic ideas from Pharmaceutical Products to Compulsion. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas

Pharmaceutical Products | View | ||

Compulsion | View |

## Bristol Myers July 13, 2020 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Bristol Myers help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bristol Myers Squibb. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bristol Myers Squibb based on widely used predictive technical indicators. In general, we focus on analyzing Bristol Myers stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bristol Myers's daily price indicators and compare them against related drivers.

Downside Deviation | 1.54 | ||

Information Ratio | (0.11) | ||

Maximum Drawdown | 8.37 | ||

Value At Risk | (1.90) | ||

Potential Upside | 2.13 |

Continue to Trending Equities. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies,
are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information
is derived directly from data published by
companies or submitted to governmental agencies which we believe are reliable, but are without our
independent verification. Therefore, we cannot assure you that the information is accurate or complete.
We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations.
Also, note that past performance is not necessarily indicative of future results. All investments carry risk,
and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee
that systems, indicators, or signals will result in profits or that they will not result in losses.
All investors are advised to fully understand all risks associated with any investing they choose to do.
Hypothetical or simulated performance is not indicative of future results.
We make no representations or warranties that any investor will, or is likely to, achieve profits
similar to those shown because hypothetical or simulated performance is not necessarily indicative
of future results. For more information please visit our
terms and condition page